Product Ref: HODOL02 Category: M
Royal Mail Tracked 24 (Signed For)
Royal Mail Special Delivery Guaranteed by 1pm
Category | POM-V |
Temperature | Ambient |
MA/VM/EU No: | 01708/4535 |
Species |
|
VMD Link | https://www.vmd.defra.gov.uk/productinformationdatabase/files/SPC_Documents/SPC_176435.PDF |
NOAH Link | |
Dosage | Amounts to be administered and administration route: For analgesia: Horse: 0.05 to 0.1 mg/kg, intravenous route, (i.e. 2.5 to 5 ml for 500 kg bw). Dog: 0.2 to 0.4 mg/kg, intravenous route, (i.e. 0.2 to 0.4 ml/10 kg bw). Rapid intravenous injection should be avoided. Butorphanol is intended for use where short duration analgesia is required. For information on the duration of analgesia that can be expected following treatment see ‘Pharmacological particulars’. However, repeat treatments of butorphanol may be administered. The need for, and timing of repeat treatment will be based on clinical response. For cases where longer duration analgesia is likely to be required, an alternative therapeutic agent should be used. Cat: 0.4 mg/kg, subcutaneous route, (i.e. 0.2 ml/5 kg bw). Cats should be weighed to ensure that the correct dose is calculated. An appropriate graduated syringe must be used to allow accurate administration of the required dose volume (e.g. insulin syringe or 1 ml graduated syringe). In the cat, butorphanol is intended for use where short to medium duration analgesia is required. For information on the duration of analgesia that can be expected following treatment see section ‘Pharmacological particulars’. Depending on the clinical response, product administration may be repeated within six hours. In the absence of an adequate analgesic response (see section ‘Special warnings for each target species’), use of an alternative analgesic agent, such as another suitable opioid analgesic and/or a non-steroidal anti-inflammatory drug, should be considered. Any alternative analgesia should take account of the action of butorphanol on opioid receptors, as described under section ‘Interactions’. If repeated administrations are required, use different injection sites. For sedation: Butorphanol can be used in combination with an α2-adrenoceptor agonist (e.g. (me)detomidine or romifidine). Adjustment of the dose will then be necessary according to the following recommendations: Horse: Detomidine: 0.01 – 0.02 mg/kg intravenous route. Butorphanol: 0.01 – 0.02 mg/kg intravenous route. Detomidine should be administered up to 5 min before butorphanol. Romifidine: 0.05 mg/kg intravenous route. Butorphanol: 0.02 mg/kg intravenous route. Romifidine can be administered concurrently or 4 min before butorphanol. Dog: Medetomidine: 0.01 – 0.03 mg/kg intramuscular route. Butorphanol: 0.1 – 0.2 mg/kg intramuscular route. Medetomidine and butorphanol can be administered concurrently. The stopper should not be pierced more than 25 times. Overdose: The main sign of overdose is respiratory depression, which, if severe, can be reversed with an opioid antagonist (e.g. naloxone). Other possible signs of overdose in the horse include restlessness/excitability, muscle tremor, ataxia, hypersalivation, decrease of gastrointestinal motility and seizure. In the cat, the main signs of overdose are incoordination, salivation, and mild convulsions. |
Withdrawals | Withdrawal periods: Horse: Meat and offal: zero days. Milk: zero hours. |